Home / Health / Asthma Drug Reduces Swallowing Issues in Esophageal Disease Trial
Asthma Drug Reduces Swallowing Issues in Esophageal Disease Trial
21 Oct
Summary
- Amgen and AstraZeneca's drug shows promise for esophageal disorder.
- The drug helped reduce swallowing difficulties in patients.
- Disease remission was achieved in 69% of patients in the trial.
Amgen and AstraZeneca have reported encouraging results from a clinical trial for their asthma drug, which is being investigated for its efficacy in treating a specific chronic inflammatory disorder of the esophagus. The latest findings, announced on Tuesday, October 20, 2026, reveal that the drug successfully reduced swallowing difficulties among patients.
Furthermore, the therapeutic intervention led to disease remission in an impressive 69% of the participants. This development extends promising data initially shared in August, when AstraZeneca indicated the drug met primary trial endpoints after 24 weeks of treatment, showing positive effects on esophageal inflammation and patient swallowing capabilities when compared to a placebo.
